02 April 2024

L to R: Dr Sarah Boyle, Prof Richard D’Andrea & Prof Michael Samuel.

Three Centre for Cancer Biology (CCB) researchers from UniSA and SA Pathology have collectively been awarded more than $1.3 million to further vital research into bowel cancer, acute myeloid leukaemia (AML) and breast cancer.

A team led by CCB scientist Professor Michael Samuel will investigate why people diagnosed with early-onset bowel cancer have a 50% chance of experiencing a relapse after surgery to remove the primary tumour. Compared to people diagnosed with late-onset bowel cancers, it is also more likely that the cancer will spread to other organs.

“At the moment we cannot predict whose tumours will return and whose won’t, resulting in some patients receiving unnecessary chemotherapy and others, who elect not to, relapsing,” Prof Samuel says.

“However, we have identified chemicals produced by tumours that affect the chances of cancer relapse. If we can block these from hijacking normal cells in their environment, this could be a new way of targeting bowel cancer.”

Prof Samuel’s team has been awarded $573,833 for this project, funded by Bowel Cancer Australia via Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme.

CCB leukaemia researcher Professor Richard D’Andrea will use a $599,392 grant from Cancer Australia to analyse genetic changes and improve precision medicine for children with acute myeloid leukaemia (AML).

Although children diagnosed with AML undergo aggressive chemotherapy, approximately 30% do not survive.

“It is now widely understood that the genes we are born with can affect our risk of developing AML and influence the response to treatment,” Dr D’Andrea says.

“Despite this knowledge, guidelines for doctors on how to best treat childhood AML patients based on their individual genetic profile are lacking. This could be leading to suboptimal outcomes in some patients.

“We will address this gap by establishing national expert guidelines for inherited genetic changes that are identified in childhood AML patients, and by improving diagnosis and prognostication of familial predisposition, leading to better treatments.”

CCB Research Fellow Dr Sarah Boyle has been awarded $199,883 from Cancer Australia and the Can Too Foundation to investigate a new way of tackling the spread of breast cancer and improving outcomes for patients.

Metastatic breast cancer is the most common cause of cancer-related related death in women and is helped by changes in the immediate environment that surrounds the breast cancer. This is influenced by rogue chemicals released from cancers as they grow.

“Breast cancer cells release chemicals that act on normal cells in their environment, which aid the cancer to spread to other organs. This project will focus on finding a way to block these chemicals that alter the environment, to stop breast cancer metastasis,” Dr Boyle says.


Media contact: Candy Gibson M:  0434 605 142 E: candy.gibson@unisa.edu.au

Professor Michael Samuel E: Michael.Samuel@unisa.edu.au
Professor Richard D’Andrea E: Richard.DAndrea@unisa.edu.au
Dr Sarah Boyle E: Sarah.Boyle@unisa.edu.au

Other articles you may be interested in